Trials / Unknown
UnknownNCT00809549
Study to Determine The Effect of a Drug Called Neupogen on Stroke Recovery
Granulocyte-Colony Stimulating Factor In Ischemic Stroke (GIST): A Pilot Study
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Ottawa Hospital Research Institute · Academic / Other
- Sex
- All
- Age
- 45 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
1. Circulating bone marrow and blood vessel precursors home in to sites of ischemia and aid regeneration of injured tissue 2. Increasing the number of circulating precursors will improve in regeneration of damaged brain following ischemic stroke.
Detailed description
We hypothesize that mobilization of bone marrow precursor cells into the blood stream will allow them to redistribute in the injured central nervous system and aid regeneration of damaged tissue. If the hypotheses is correct, it predicts that G-CSF treatment will improve the functional outcome of patients following acute ischemic stroke. Underlying this work are the following considerations: * Currently the clinical and functional outcomes following ischemic strokes are poor and require new treatment strategies. * G-CSF administration is a well established routine treatment for the mobilization of hematopoietic and endothelial precursors from the bone marrow into the circulation. * Acute ischemia locally increases factors that direct circulating bone marrow derived cells to home to these sites of injury. * Evidence exists that bone marrow derived cells are able to repopulate different tissues including those of the CNS. * Acute ischemic injury to the central nervous system provides a milieu for the regeneration of neural tissue.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Filgrastim | 10 ug/kg sc once daily x 4 days. Repeated once, 6 weeks later. |
Timeline
- Start date
- 2006-07-01
- Primary completion
- 2013-04-01
- Completion
- 2013-04-01
- First posted
- 2008-12-17
- Last updated
- 2012-07-13
Locations
2 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT00809549. Inclusion in this directory is not an endorsement.